GC
RARE icon

Guggenheim Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Guggenheim Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
68,803
+19,666
+40% +$443K 0.01% 834
2025
Q4 		$1.13M Buy
49,137
+2,061
+4% +$67.8K 0.01% 886
2025
Q3 		$1.42M Buy
47,076
+1,767
+4% +$53K 0.01% 807
2025
Q2 		$1.65M Sell
45,309
-1,351
-3% -$48.7K 0.01% 709
2025
Q1 		$1.69M Buy
46,660
+1,438
+3% +$59.8K 0.02% 685
2024
Q4 		$1.9M Buy
45,222
+670
+2% +$33.2K 0.02% 671
2024
Q3 		$2.47M Buy
44,552
+3,956
+10% +$202K 0.02% 753
2024
Q2 		$1.67M Buy
40,596
+4,701
+13% +$201K 0.01% 882
2024
Q1 		$1.68M Buy
35,895
+8,186
+30% +$386K 0.01% 958
2023
Q4 		$1.33M Buy
27,709
+1,952
+8% +$75.7K 0.01% 1029
2023
Q3 		$918K Buy
25,757
+6,207
+32% +$246K 0.01% 1143
2023
Q2 		$902K Sell
19,550
-3,654
-16% -$169K 0.01% 1214
2023
Q1 		$930K Sell
23,204
-7,546
-25% -$324K 0.01% 1220
2022
Q4 		$1.42M Buy
30,750
+441
+1% +$17.3K 0.01% 997
2022
Q3 		$1.25M Sell
30,309
-90
-0.3% -$4.63K 0.01% 1032
2022
Q2 		$1.81M Buy
30,399
+1,415
+5% +$87.1K 0.01% 929
2022
Q1 		$2.1M Buy
28,984
+1,460
+5% +$102K 0.01% 996
2021
Q4 		$2.31M Buy
27,524
+2,845
+12% +$231K 0.01% 988
2021
Q3 		$2.23M Sell
24,679
-109
-0.4% -$9.85K 0.01% 1003
2021
Q2 		$2.36M Buy
24,788
+2,543
+11% +$265K 0.01% 1006
2021
Q1 		$2.53M Buy
22,245
+3,866
+21% +$526K 0.02% 911
2020
Q4 		$2.54M Sell
18,379
-13,486
-42% -$1.6M 0.02% 867
2020
Q3 		$2.62M Sell
31,865
-9,628
-23% -$798K 0.02% 780
2020
Q2 		$3.25M Sell
41,493
-7,108
-15% -$470K 0.03% 690
2020
Q1 		$2.16M Sell
48,601
-9,539
-16% -$495K 0.02% 759
2019
Q4 		$2.48M Buy
58,140
+10,672
+22% +$440K 0.02% 954
2019
Q3 		$2.03M Buy
47,468
+3,839
+9% +$209K 0.02% 1012
2019
Q2 		$2.77M Sell
43,629
-2,296
-5% -$146K 0.02% 913
2019
Q1 		$3.19M Sell
45,925
-3,476
-7% -$199K 0.03% 863
2018
Q4 		$2.15M Buy
49,401
+3,676
+8% +$201K 0.02% 1009
2018
Q3 		$3.49M Sell
45,725
-1,605
-3% -$131K 0.02% 931
2018
Q2 		$3.64M Sell
47,330
-10,317
-18% -$666K 0.02% 899
2018
Q1 		$2.94M Buy
57,647
+545
+1% +$27.4K 0.01% 1368
2017
Q4 		$2.65M Sell
57,102
-11,892
-17% -$583K 0.01% 1456
2017
Q3 		$3.67M Buy
68,994
+16,589
+32% +$983K 0.01% 1243
2017
Q2 		$3.25M Buy
52,405
+6,684
+15% +$403K 0.01% 1272
2017
Q1 		$3.1M Sell
45,721
-1,496
-3% -$114K 0.01% 1327
2016
Q4 		$3.32M Sell
47,217
-4,960
-10% -$352K 0.01% 1278
2016
Q3 		$3.7M Sell
52,177
-6,597
-11% -$421K 0.01% 1200
2016
Q2 		$2.88M Buy
+58,774
New +$3.8M 0.01% 1324
2016
Q1 		– Sell
-65,713
Closed -$7.37M – 2981
2015
Q4 		$7.37M Buy
65,713
+7,622
+13% +$762K 0.02% 866
2015
Q3 		$5.59M Buy
58,091
+31,932
+122% +$3.66M 0.02% 976
2015
Q2 		$2.68M Buy
+26,159
New +$2.03M 0.01% 1553
2014
Q4 		– Sell
-67,043
Closed -$3.79M – 3087
2014
Q3 		$3.79M Buy
+67,043
New +$3.37M 0.01% 1357

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Guggenheim Capital's RARE Position: Q1 2026 in Review

Guggenheim Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 40% in Q1 2026, buying an estimated $443K and bringing the position to 68,803 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #834.

Guggenheim Capital first reported a position in RARE in Q3 2014 and has held it in 44 quarters since. The position peaked at $7.37M in Q4 2015. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Guggenheim Capital held 68,803 shares of Ultragenyx Pharmaceutical worth $1.44M as of Q1 2026.
  • Guggenheim Capital bought 19,666 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $443K.
  • Ultragenyx Pharmaceutical made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #834 holding.
  • Guggenheim Capital first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 44 quarters since.
  • Guggenheim Capital's Ultragenyx Pharmaceutical position peaked at $7.37M in Q4 2015.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.